Spruce Biosciences, Inc.

0.56 USD
+0.02 (+4.13%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Spruce Biosciences, Inc. stock is down -17.29% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 June’s closed higher than May. 50% of analysts rate it a buy.

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc. focuses on developing and commercializing novel therapies for rare endocrine disorders. The company is developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia.

  • Oppenheimer
    Thu Jun 13, 07:56
  • HC Wainwright & Co.
    Wed Jun 5, 07:20